Scripps Research Institute Scientists Create Potential Vaccine Ingredient for Childhood Respiratory Disease
The feat bolsters rational vaccine design approach that could also be applied to other challenging viruses including HIV and influenza
Embargo expired: 5-Feb-2014 1:00 PM EST
Source Newsroom: Scripps Research Institute
Newswise — LA JOLLA, CA—February 5, 2014—Scientists at The Scripps Research Institute (TSRI) have invented a new method for designing artificial proteins, and have used it to make key ingredients for a candidate vaccine against a dangerous virus, respiratory syncytial virus (RSV), a significant cause of infant mortality. The virus has been resistant to current vaccine-design strategies.
With the help of collaborating laboratories, the scientists were able to apply the new method, which uses a “rational design” approach to making vaccines focused on specific binding areas (epitopes) on the virus. The result was designer vaccine proteins that the scientists showed stimulate the production of the desired virus-neutralizing antibodies in rhesus macaques.
“This was a proof-of-principle demonstration of a technology that could be very useful against HIV, influenza and other highly variable viruses that have been difficult to stop using traditional vaccine-design strategies,” said William R. Schief, associate professor of immunology at TSRI.
“The achievement represents the confluence of recent technological advances in computational biology, structural biology and immune monitoring, and offers great potential for accelerating development of next generation vaccines against major global diseases,” said Wayne C. Koff, chief scientific officer at IAVI, the International AIDS Vaccine Initiative, which helped to fund the studies.
The research is reported in the journal Nature on February 5, 2014.
Folding from Loops
The new protein-design method represents a significant advance over previous methods.
“One approach we and others have taken has been to transplant a protein fragment of interest, for example one that mimics a particular structure on a virus, onto an existing protein ‘scaffold,’” said TSRI Research Associate Bruno E. Correia, a member of the Schief laboratory at the time of the study and lead author of the new report. “While this approach often works well to mimic the structure of a viral epitope, it has never successfully induced neutralizing antibodies, and in some cases this method falls short of even producing viable vaccine candidates.”
In these difficult cases, the scaffold structure fails to stabilize the transplanted fragment, resulting in an imperfect mimic of the virus and consequent loss of immune-stimulating properties.
The TSRI scientists wanted a way to design scaffold proteins from scratch—proteins that would fit around their functional fragments more naturally, and would do a better job of stabilizing them.
The result was a new software app, “Fold from Loops,” for designing proteins that fold up around a functional fragment of interest. For a proof-of-principle demonstration, the scientists decided to attempt one of the most important current protein-design challenges: making a new protein that mimics a particular epitope on a virus, and thus can serve as a key component of a vaccine.
The Promise of Rational Vaccine Design
Researchers want to be able to stimulate antibody reactions against highly specific epitopes because some infectious agents seem unstoppable by traditional methods of immunization.
Virtually all existing viral vaccines, for example, use whole (killed or weakened) virus particles or entire viral proteins to stimulate antibody reactions. These vaccines display virtually the same large set of viral epitopes that the immune system would encounter during a natural infection.
Yet some viruses, such as HIV and influenza viruses, effectively conceal their truly vulnerable epitopes during natural infections, displaying mostly “decoy” structures that change from one viral generation to the next. Only vaccines that can artificially stimulate large numbers of antibodies—against just the vulnerable epitopes—are likely to provide broad protection against such viruses.
Scientists know how to sift through blood samples of virus-exposed patients to find the rare, “broadly neutralizing” antibodies that hit those vulnerable epitopes. They also know how to map the precise atomic structures of these antibodies and their corresponding epitopes, using X-ray crystallography.
“What we haven’t been able to do is to take that information about broadly neutralizing antibodies and their epitopes and translate it into effective, epitope-focused vaccines,” said Correia.
A Candidate RSV Vaccine
For the test case, the team used the Fold from Loops software to design proteins that incorporate and stabilize a broadly neutralizing epitope on respiratory syncytial virus (RSV), a significant cause of infant mortality for which no preventive vaccine is yet available. Winnowing thousands of design possibilities down to four that seemed to have the best properties, the team turned them over to collaborating laboratories for preclinical testing and analysis.
In rhesus macaque monkeys, whose immune systems are quite similar to humans’, the designer “immunogen” proteins showed great promise. After five immunizations, 12 of 16 monkeys were producing robust amounts of antibodies that could neutralize RSV in the lab dish.
“It’s unusual to take a newly designed protein and immunize rhesus macaques with it,” said Schief. “We were fortunate to collaborate with Philip Johnson at Children’s Hospital in Philadelphia, whose laboratory performed those immunizations.”
Analyses of the animals’ immune responses were conducted at Johnson’s laboratory and at the laboratory of James E. Crowe, Jr., at Vanderbilt University Medical Center and in Barney Graham's lab at the NIH/NIAID Vaccine Research Center.
At the laboratory of Roland K. Strong at Fred Hutchinson Cancer Research Center in Seattle, researchers performed X-ray crystallography of two neutralizing monoclonal antibodies produced by the macaques—antibodies that had never been described before—and confirmed that each hit the desired virus epitope.
Having proven the principle of epitope-specific design, Schief and his colleagues now hope to continue this line of research and produce a working RSV vaccine. “RSV is estimated to cause nearly seven percent of all human deaths worldwide in children ages one month to one year,” said Schief. “Beyond that, RSV sends millions of kids to the hospital and right now there is no licensed vaccine. So we are going to push hard to see if we can make an RSV vaccine for infants and children using these new technologies. We’re also trying to improve this protein design method further and apply it to other vaccine projects including HIV and influenza vaccines.”
Other co-authors of the study, “Proof of Principle for Epitope-Focused Vaccine Design,” were John T. Bates of Vanderbilt University, Rebecca J. Loomis of the Children's Hospital of Philadelphia Research Institute, Gretchen Baneyx of the University of Washington, Christopher Carrico of the Fred Hutchinson Cancer Research Center, Joseph G. Jardine of TSRI and the University of Washington, Peter Rupert and Colin Correnti of the Fred Hutchinson Cancer Research Center, Oleksandr Kalyuzhniy of the University of Washington and TSRI, Vinayak Vittal of the University of Washington, Mary J. Connell of the Children's Hospital of Philadelphia Research Institute, Eric Stevens and Alexandria Schroeter of the University of Washington, Man Chen and Barney S. Graham of the National Institute of Allergy and Infectious Diseases; Skye MacPherson, Andreia M. Serra and Yumiko Adachi of the University of Washington and TSRI; Margaret A. Holmes (deceased) of the Fred Hutchinson Cancer Research Center; Yuxing Li of IAVI and TSRI; Rachel E. Klevit of the University of Washington; Richard T. Wyatt of IAVI and TSRI; and David Baker of the University of Washington.
Funding for the research was provided by the National Institute of Allergy and Infectious Diseases (grants 5R21AI088554, 1UM1AI100663, 1R01AI102766-01A1, P30AI36214); the International AIDS Vaccine Initiative Neutralizing Antibody Consortium; the International AIDS Vaccine Initiative Neutralizing Antibody Center; the March of Dimes; the Bill and Melinda Gates Foundation; The Children’s Hospital of Philadelphia; and the Fundação para a Ciência e a Tecnologia of Portugal.
About The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including three Nobel laureates—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.